Progenics Pharmaceuticals, Inc. Securities Litigation

If you purchased a significant amount of shares of Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Progenics Pharmaceuticals Inc.
Date Filed:November 22nd, 2019
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:October 2nd, 2019
Class End Date:November 22nd, 2019

According to the Complaint, Progenics Pharmaceuticals, Inc. is an oncology company focused on the development and commercialization of targeted medicines and artificial intelligence to find, fight and follow cancer.
The Company's pipeline includes therapeutic agents designed to precisely target cancer and prostate-specific membrane antigen targeted imaging agents for prostate cancer.

This action stems from a proposed transaction announced on October 2, 2019, pursuant to which Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., will acquire Progenics in an all-stock transaction.

On November 12, 2019, Defendants caused the Form S-4 Registration Statement (the "S-4") to be filed with the SEC in connection with the Proposed Transaction. The S-4 solicits the Company's shareholders to vote
in favor of the Proposed Transaction. The Complaint alleges that the S-4 is materially incomplete and misleading, in violation of Sections 14(a) and 20(a) of the Exchange Act.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Progenics Pharmaceuticals Inc.

First Identified Complaint

Martin Johnson, et al. v. Progenics Pharmaceuticals, Inc., et al.

Date Filed:November 22nd, 2019
Class Period Start:October 2nd, 2019
Class Period End:November 22nd, 2019
First Identified Complaint Filings
#Document TitleFiling Date